Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07597902 · ClinicalTrials.gov registry record · Phase 2
SARS-CoV-2 and Herpesvirus Inhibition for Ending Long COVID Dysfunction
A Phase 2 study, sponsored by Icahn School of Medicine at Mount Sinai.
- Not yet
- Registry status
- Phase 2
- Development phase
- 150
- Enrollment target
NCT07597902 is a Phase 2 study that has not yet begun recruiting, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 150 participants.
The verdict
NCT07597902, a Phase 2 study, has not yet begun recruiting, sponsored by Icahn School of Medicine at Mount Sinai.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 150 participants
- Enrollment target
Study Summary
The purpose of this research study is to test if the combination of three drugs, valacyclovir, celecoxib, and Paxlovid will decrease the symptoms of Long COVID in adults compared to a placebo (this does not contain the medications).
Interventions
- DRUG Placebo
- DRUG Celecoxib
- DRUG Valacyclovir
- DRUG Paxlovid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2026-06-01 |
| Est. Completion | 2028-06-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07597902
The ClinicalTrials.gov registry entry for NCT07597902 describes a study currently listed as not yet recruiting, categorized as Phase 2. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Icahn School of Medicine at Mount Sinai, which has 708 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT07597902 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07597902 about?
NCT07597902 is a clinical study titled "SARS-CoV-2 and Herpesvirus Inhibition for Ending Long COVID Dysfunction". The purpose of this research study is to test if the combination of three drugs, valacyclovir, celecoxib, and Paxlovid will decrease the symptoms of Long COVID in adults compared to a placebo (this does not contain the medications).
What is the current status of trial NCT07597902?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 150 participants. The study started on 2026-06-01. Estimated completion is 2028-06-30.
What interventions are being tested in trial NCT07597902?
The interventions under investigation include: Placebo (DRUG), Celecoxib (DRUG), Valacyclovir (DRUG), Paxlovid (DRUG).
Who is sponsoring clinical trial NCT07597902?
This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.